We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two ...

Bernstein raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes Gilead ...

Gilead (GILD) stock won an upgrade from Deutsche Bank on HIV treatment boost, while Merck (MRK) stock received a downgrade on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025. Adjusted earnings per share (EPS) of $1.90 beat the Zacks Consensus ...

Q4 2024 Earnings Call Feb 11, 2025, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participant ...

智通财经APP获悉，2月18日，吉利德(GILD.US)宣布FDA已接受lenacapavir用于HIV暴露前预防(PrEP)的新药申请(NDA)，PDUFA预定审批日期为2025年6月19日。Lenacapavir是一款First-in-class ...

Gilead Sciences (GILD) reported $7.57 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 6.4%. EPS of $1.90 for the same period compares to $1.72 a ...

Below is a chart showing VRT's trailing twelve month trading history, with the $85 strike highlighted in orange: Gilead Sciences Inc (Symbol: GILD) saw options trading volume of 40,770 contracts ...